Released Nov 12, 2025, before the open
10-Q filed Nov 12, 2025, 43 days after period end · 0001576885-25-000104
Q3 2025 · 10-Q
Revenue—
Net Income-$26.45M-$26.45M N/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.44-$0.44 N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$26,513,000N/M
Operating Cash Flowderived-$30,489,000N/M
Free Cash Flowderived-$30,489,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Net Income | -$26.45M | -$29.77M | -$12.96M | -$10.71M |
| EPS Diluted | -$0.44 | -$0.50 | -$0.24 | -$0.26 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR